 MARLBOROUGH, Mass., April 10, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced new in vivo data showing intratumoral IT treatment with the murine PD-1 targeting INTASYL mPH-762 inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models. 